You are here

Article Text

Article menu
Download PDFPDF
Letter
Use of inhaled corticosteroids in children
  1. M Devoy
  1. Vice President, Respiratory Clinical Development & Medical Affairs, GlaxoSmithKline Research & Development Ltd, Greenford Road, Greenford, Middlesex UB6 0HE, UK; Mike.B.Devoy@gsk.com

https://doi.org/10.1136/adc.88.5.461

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with interest the article Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom by Todd et al and the accompanying editorial in the December issue of Archives.

    In the reported cases, the children had been administered substantially (up to 5 times) higher than the Glaxo SmithKline (GSK) Core Data Sheet recommended Flixotide dose of 400 mcg/day and use of fluticasone (FP) at such doses is certainly not endorsed by GSK. Within the recommended doses, there are a wealth of data from controlled clinical trials that Flixotide is a well tolerated and effective drug in adults and children. …

    View Full Text